Sarilen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sarilen

Quick Facts

Property Description
Active ingredient Losartan Potassium
Form Oral Tablet (Film-coated)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Systemic control of high blood pressure
Origin Synthetic, Non-peptide molecule

What Type of Medicine is Sarilen, and What is its Composition?

Sarilen is the trade name for a systemic medication whose active chemical substance is Losartan Potassium. It is officially classified as an Angiotensin II Receptor Blocker (ARB), a class of drugs belonging to the wider category of Antihypertensive Agents. This drug is a synthetic, non-peptide molecule delivered for consumption as an oral tablet. Losartan, as a single-entity product, provides its therapeutic action using only the Losartan Potassium salt, which is formulated with standard pharmaceutical excipients suitable for a solid tablet form designed for long-term daily use. Losartan Potassium functions as an antihypertensive and is an Angiotensin II receptor antagonist.


What is the Purpose of Losartan?

The primary role of Losartan is the sustained reduction of high blood pressure (hypertension). This medication helps manage pressure by preventing a potent, naturally occurring body chemical from causing blood vessels to narrow. By preventing this narrowing and promoting vasodilation, Losartan effectively reduces the overall resistance in the blood vessels, achieving its general purpose of easing the strain on the heart and major arteries. Losartan plays a key role in reducing cardiovascular risk in hypertensive patients and is clinically recognized for its long-term benefits in mitigating the risk factors associated with elevated blood pressure. This sustained decrease in systemic pressure is critical for the long-term protection and circulatory well-being of vital organs, including the kidneys.


The Difference: Losartan vs. Related Antihypertensives

Losartan (ARB) works differently from another common class of blood pressure medicines called ACE Inhibitors (e.g., lisinopril). ARBs provide a validated alternative to ACE inhibitors in patients who cannot tolerate the adverse effects of the latter. While both classes target the Renin-Angiotensin-Aldosterone System (RAAS), ACE inhibitors prevent the formation of the vasoconstricting hormone Angiotensin II. In contrast, ARBs like Losartan block the AT1 receptor where that hormone attempts to act, making the ARB mechanism a targeted alternative often utilized for patients who do not tolerate the dry cough associated with ACE Inhibitors. Losartan itself is distinct from newer ARBs, having been established in clinical practice for decades with a documented profile of long-term efficacy and safety.

Regulatory References

  1. NIH/MedlinePlus

What side effects are possible with Sarilen?

Possible Side Effects and Safety Information

The safety profile of Sarilen (Losartan Potassium) is formally defined by government regulatory agencies through classifications based on the frequency and the physiological systems affected. These classifications dictate the spectrum of officially documented safety findings and high-level constraints.

Adverse Reaction Classification

Side effects documented in regulatory labeling are categorized by frequency, which reflects their occurrence rate in clinical studies:

  • Common Reactions: Reactions that appear in approximately 1 to 10 out of every 100 patients. These often include dizziness, fatigue, upper respiratory tract infection, and nasal congestion.
  • Uncommon Reactions: These are reported less frequently, in less than 1 out of 100 patients, and may involve effects such as vertigo, palpitations, rash, or sleep disorders.

Serious Adverse Reactions and Systemic Safety

Adverse reactions that are considered serious or life-threatening are explicitly documented, even if they occur rarely (less than 1 in 1,000 patients). The most clinically significant serious reaction listed in official documents is Angioedema, which involves swelling of the face, lips, tongue, and/or throat. Other rare but serious documented effects include Hepatitis and Rhabdomyolysis. The official safety documents also note that the risk of Hyperkalemia (elevated potassium levels) is a safety consequence when Losartan is co-administered with potassium-sparing agents.

Population-Specific Safety Constraints

The use of Losartan is subject to specific safety limitations defined in regulatory documents:

  • Pregnancy: Losartan is strictly contraindicated during the second and third trimesters due to the significant risk of fetal injury and death.
  • Hepatic Impairment: The medicine is contraindicated in patients with severe hepatic impairment due to the potential for significantly increased exposure to the drug.
  • Time-Related Pattern: Symptomatic Hypotension (low blood pressure) is noted as being more likely to occur early in therapy or following a dose increase, particularly in volume-depleted patients. The official labeling also contraindicates the use of Losartan in combination with aliskiren in patients with diabetes.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented clinical manifestations of overdose with Losartan Potassium (Sarilen) and the emergency actions mandated by government health authorities.


Documented Overdose Manifestations and Risks

Clinical signs of overdosage are strongly linked to the drug’s primary action of lowering blood pressure. The most frequently documented manifestations in regulatory sources include hypotension (severely low blood pressure) and tachycardia (fast heart rate); less commonly, bradycardia (slow heart rate) may occur. Severe hypotension can result in symptoms such as dizziness and syncope (fainting).

Classification Element Regulatory Description
Antidote Information No specific antidote is known for Losartan overdose.
Management Measure The substance is not expected to be removed by hemodialysis.
Required Treatment Symptomatic and supportive treatment must be instituted for patients experiencing symptomatic hypotension.

Required Emergency Actions

Immediate medical attention must be sought for all suspected overdose cases. Official guidance mandates contacting emergency services immediately if the affected person collapses, has a seizure, experiences difficulty breathing, or cannot be awakened. Individuals are also directed to contact a Poison Control Center for guidance regarding suspected overdosage.


Population-Specific Consideration

For neonates who have had in utero exposure and develop oliguria or hypotension, attention must be directed toward supporting blood pressure and renal perfusion; exchange transfusion or dialysis may be required in these specific neonatal cases.

Therapeutic Uses of Sarilen

What Sarilen Treats: Main Uses and Benefits

Sarilen is commonly used to help with conditions involving episodic or fluctuating manifestations related to high blood pressure. It is used to provide symptomatic relief and offers supportive therapeutic benefit, and is considered relevant in conditions marked by increased physiological stress, including specific conditions associated with high blood pressure where supportive management is appropriate.

This medication helps address groups of symptoms that may appear suddenly or fluctuate over time due to systemic imbalance. This supportive relief is often utilized during phases where the patient experiences heightened discomfort. It contributes to improved comfort and assists with maintaining functional stability when symptoms create noticeable physiological strain.

Quick Facts on Therapeutic Domains

  • Relief for: Symptoms related to systemic imbalance
  • Applied when: Supportive symptom management is appropriate
  • Helps manage: Symptoms that interfere with daily functioning

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Sarilen (Losartan Potassium) is approved for use in adults and pediatric patients aged 6 years and older for the treatment of hypertension. The regulatory profile defines distinct groups for whom use is strictly prohibited or restricted.

Contraindicated Populations

Official regulatory labeling states that Sarilen is contraindicated in several specific populations. This includes women who are in the second or third trimester of pregnancy due to the documented risk of fetal injury and patients with a known hypersensitivity to losartan or any of its components. A further absolute prohibition applies to patients with severe hepatic impairment and to diabetic patients who are concurrently receiving the drug aliskiren.

Restricted and Non-Eligible Groups

Use is not recommended in children under 6 years old, as safety and effectiveness have not been established in this age group, and in pediatric patients with specific markers of severe renal impairment (low estimated GFR). The medicine is also not recommended during the first trimester of pregnancy or while breastfeeding. Eligibility is restricted in patients with mild-to-moderate liver impairment or in states of volume/salt depletion, and requires conditional use as defined by official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sarilen (Losartan Potassium) has officially documented interactions classified by regulatory agencies based on pharmacokinetic changes and pharmacodynamic risks.


Contraindicated and Restricted Combinations

Co-administration with Aliskiren is contraindicated in patients with diabetes due to an increased risk of severe outcomes, including renal impairment and hyperkalemia. The combination with Sparsentan is also prohibited by regulatory agencies. Furthermore, the dual blockade of the Renin-Angiotensin System, involving co-administration with ACE Inhibitors or other ARBs, is generally not recommended.


Pharmacokinetic and Exposure Modification

Losartan’s systemic exposure (AUC) is subject to modification by specific enzyme inhibitors and inducers. Co-administration with Fluconazole is documented to increase losartan exposure by approximately 70% while simultaneously reducing the exposure of its active metabolite. Conversely, co-administration with Phenobarbital is documented to reduce the exposure of both losartan and its active metabolite.


Pharmacodynamic and Substance Interactions

Concomitant use with agents that increase serum potassium, such as potassium-sparing diuretics and potassium supplements, carries a documented risk of hyperkalemia. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can result in compromised renal function and reduce the antihypertensive effect. Additionally, co-administration with Lithium is associated with a documented risk of lithium toxicity. Official labeling notes that patients with hepatic impairment exhibit significantly higher Losartan exposure than healthy individuals.

Mechanism of Action

Sarilen is classified as an Angiotensin II Receptor Blocker (ARB). Its primary biological targets are the Type-1 Angiotensin II receptors (AT1 receptors) found on various tissues, including vascular smooth muscle, adrenal glands, and kidney cells. Sarilen functions as a selective, competitive antagonist at the AT1 receptor site.

By occupying and inhibiting the AT1 receptor, Sarilen prevents the binding and action of the endogenous vasoconstrictive hormone, Angiotensin II. Intracellularly, this blockade prevents the AT1 receptor-mediated activation of phospholipase C and subsequent downstream signaling cascades, including the generation of diacylglycerol and inositol triphosphate. This signaling modification results in a reduction of intracellular calcium release in vascular smooth muscle cells. The decreased intracellular calcium prevents the phosphorylation of myosin light chain, thereby inhibiting smooth muscle cell contraction.

At a system-level, the modulation of this pathway results in vasodilation and a reduction in Total Peripheral Resistance (afterload). Furthermore, the blockade reduces the Angiotensin II-mediated release of aldosterone from the adrenal cortex, promoting the excretion of sodium and water. The combined consequences include a decrease in systemic vascular tone and a modulation of fluid volume.

Dosage and Administration Information

How to Use Sarilen: Administration Guidelines

Sarilen (Losartan Potassium) is an oral medication with a standardized administration protocol. The medicine is for oral use and is available as a tablet in strengths of 25 mg, 50 mg, and 100 mg, as well as an oral suspension.


Dosing and Frequency

Administration is typically a once-daily regimen. The standard adult starting dose for major indications is 50 mg once daily. The dose may subsequently be increased to a maximum of 100 mg once daily to achieve the desired effect. For patients identified as having intravascular volume depletion or mild-to-moderate hepatic impairment, a lower initial dose of 25 mg once daily is utilized.

Pediatric patients (aged 6 to 16) with hypertension begin at an initial dose of 0.7 mg/kg up to 50 mg, but use is not recommended for children under 6 years old.


Administration Conditions and Handling

Losartan may be taken with or without food, providing flexibility in scheduling. It should be taken at approximately the same time each day to maintain consistent levels. The 50 mg tablet is typically scored and may be divided for specific dosing needs. For the suspension form, the solution must be shaken prior to measurement and ingestion.

In the event of a missed dose, the instruction is to take the next dose as normal and not take a double dose to compensate. The full therapeutic effect is often established within three to six weeks of consistent use.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Sarilen

The information below summarizes the official research conducted on Sarilen (Losartan Potassium), focusing on the types of studies performed, the patient populations examined, and the general patterns described in the scientific findings. This overview is purely descriptive and does not offer medical advice or instructions on use.


Evidence for Use in High Blood Pressure (Hypertension)

Research exploring Sarilen for managing high blood pressure includes a large number of Randomized Controlled Trials (RCTs) and systematic reviews. These trials were designed to measure changes in systolic and diastolic blood pressure readings over short periods. Findings describe patterns where lower blood pressure readings were observed in the group receiving the medicine compared to baseline readings in the observed adult populations. Researchers also explored patterns related to long-term cardiovascular events.

Evidence for Use in Diabetic Kidney Disease

Sarilen was studied for its role in patients with Type 2 diabetes who also have high blood pressure and evidence of kidney disease (nephropathy). Key research involved multi-year, placebo-controlled trials that monitored a composite outcome tracking the progression of the renal condition.

Findings described patterns where differences in the composite renal outcome were measured between the Losartan group and the placebo group. The measured levels of proteinuria were reported to be different in the observed populations compared to baseline measurements. This evidence helps contextualize how patients' kidney function evolved during the study period.

Evidence for Use in High Blood Pressure with Left Ventricular Hypertrophy (LVH)

One major, long-term comparative RCT was conducted during the evaluation of Sarilen in patients with high blood pressure and Left Ventricular Hypertrophy (LVH). Studies observed patterns related to stroke incidence. Differences in the measured incidence of fatal and non-fatal stroke were noted between the Losartan group and the comparator group (a beta-blocker) in the overall patient population studied.


What is Still Uncertain About Sarilen Research

Key research limitations include the fact that subgroup findings are uncertain for specific ethnic populations, such as the observed difference in stroke outcome for Black patients with LVH. Comparative evidence is lacking for many specific clinical scenarios, and the long-term effects are not fully established beyond the primary study follow-up periods. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. NIH MedlinePlus Drug Information: Losartan

Frequently Asked Questions (FAQ)

Common questions about Sarilen (FAQ)

Q: Can Sarilen be taken with common pain relievers like ibuprofen?

A: Regulatory documents indicate that caution is advised when using Losartan with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen. This combination is noted to potentially increase the risk of kidney function issues and may lessen the blood pressure-lowering effect of Sarilen. Official guidance notes that medical oversight is recommended when proceeding with this combination.

Q: Is Sarilen considered a long-term or short-term treatment?

A: Official information and clinical studies, including those on cardiovascular events and kidney disease, demonstrate that Losartan is approved for the sustained, long-term management of high blood pressure. These studies often involve follow-up periods spanning multiple years. The use of the medicine is intended to manage a long-term condition.

Q: Can taking Sarilen affect my ability to drive or operate machinery?

A: Official safety documents list dizziness and fatigue as common side effects of Sarilen. Official guidance indicates that due to the potential for dizziness, activities such as driving or operating machinery may be affected.

Q: What does it mean that Sarilen is a 'non-selective modulator'?

A: The official mechanism of action describes Losartan as a selective, competitive antagonist of the Angiotensin II AT1 receptor. This means the medicine is designed to specifically target and block a particular type of receptor site in the body to prevent a blood-vessel-narrowing chemical from taking effect.

Q: Can Sarilen be split or crushed to make it easier to swallow?

A: The 50 mg tablet is officially scored and may be divided (split) for specific dosing needs as directed by a prescriber. However, official regulatory information does not typically authorize or recommend crushing the tablet unless specified in the official product information.

Q: How quickly does Sarilen usually start working?

A: After taking an oral dose, the main active component of Sarilen reaches its peak concentration in the bloodstream in approximately three to four hours. However, the full therapeutic effect of blood pressure lowering is generally observed within three to six weeks of consistent daily use.

Q: Does Sarilen interact with blood pressure medication?

A: Yes, regulatory documents list interactions with other medicines used for blood pressure. These include ACE inhibitors and Aliskiren, the combination of which is generally not recommended due to the risk of combined effects. Additionally, co-administration with diuretics (water pills) is associated with risks like low blood pressure or electrolyte imbalance.

Q: What are the signs of a serious side effect from Sarilen?

A: Serious, though rare, documented effects include Angioedema, which involves swelling of the face, lips, or throat, and Hepatitis, which can cause yellowing of the skin and eyes. The safety profile also documents Hyperkalemia (high potassium levels) as a risk, with potential signs including muscle weakness or irregular heart rhythm.

Q: I've heard Sarilen can make you dizzy. How common is that?

A: Dizziness is classified in official safety data as a common side effect. This classification indicates that the effect was observed in approximately 1 to 10 out of every 100 patients (1% to 10%) during the clinical trials.

Q: Is Sarilen safe to use if I have kidney problems?

A: The medicine is approved for use in certain patients with Type 2 diabetes and kidney disease. Official information specifies that a lower starting dose may be necessary for patients with existing mild-to-moderate renal impairment. The use of Sarilen may be restricted or contraindicated in cases of severe kidney impairment.

Q: Does Sarilen have a risk of withdrawal symptoms if I stop taking it?

A: The official product information does not define a formal withdrawal syndrome. Abruptly stopping any medicine for high blood pressure can cause a rapid increase in blood pressure (rebound hypertension) or a return of the original condition. Any discontinuation of the medicine is typically managed under the supervision of a healthcare provider.

Q: Are there any specific foods or drinks to avoid while using Sarilen?

A: Yes. Official labeling provides warnings regarding the use of supplements that may increase potassium levels. Due to the risk of high potassium (hyperkalemia), the label warns against the use of potassium supplements and salt substitutes containing potassium unless specified by a prescribing physician.

Q: Do the side effects of Sarilen usually go away after a few weeks?

A: Regulatory-derived patient information sheets suggest that some common side effects, such as headaches, may often start to diminish or go away after the first week of taking the medicine. However, this pattern is not guaranteed for every side effect or for every patient.

Q: Is Sarilen a controlled substance?

A: Losartan is classified as a standard human prescription drug (Rx Only) by the FDA. It is not listed as a controlled substance under the U.S. Drug Enforcement Administration (DEA) scheduling system.

Q: Is there a generic version of Sarilen available?

A: Yes. The active ingredient in Sarilen, Losartan Potassium, has been approved by the FDA for generic production. As a result, the active ingredient is widely available under its generic name.

Q: Does alcohol change the effects of Sarilen?

A: While alcohol is not explicitly listed as a formal drug interaction, official guidance indicates that limiting alcohol intake is common practice. This is due to the potential for alcohol to worsen the common side effects of Sarilen, such as dizziness and low blood pressure (hypotension).

Q: What if I take too much Sarilen by accident?

A: Official overdose documents indicate that taking too much Sarilen can lead to symptomatic hypotension, which is severely low blood pressure. Other effects noted in overdose reports include a very fast heartbeat (tachycardia) or, less commonly, a very slow heartbeat (bradycardia).

Q: Are there any long-term side effects associated with Sarilen use?

A: The official safety data includes information on reactions reported not only during clinical trials but also through post-marketing surveillance (long-term use). Rare but serious effects such as Hepatitis and Rhabdomyolysis have been observed in these long-term reports.

Q: How long after taking Sarilen does the effect last?

A: The main active component (metabolite) has a terminal half-life ranging from six to nine hours. However, the drug is formulated to ensure that the blood pressure-lowering effect persists to cover the full 24-hour period required for once-daily dosing.

Q: Can Sarilen be used by elderly people (over 65)?

A: Clinical trials and regulatory information have established that Losartan is effective and may be used in older hypertensive patients (those over 65). Dosage adjustments are generally based on individual patient characteristics rather than age alone.

Q: Is Sarilen an immunosuppressant?

A: Sarilen (Losartan) is classified as an Angiotensin II Receptor Blocker (ARB), and its primary purpose is to lower blood pressure by modulating the cardiovascular system. It is not classified as an immunosuppressant.

Q: What does the term 'contraindication' mean for Sarilen?

A: For Sarilen, a contraindication describes specific conditions, such as severe liver impairment or second/third-trimester pregnancy, where the drug must not be used. In these documented situations, the risk of serious harm or adverse outcome is noted to outweigh any possible benefit.

Q: Can Sarilen cause mood changes or anxiety?

A: Official safety documents list sleep-related issues like insomnia (trouble sleeping) as a common side effect and sleep disorder as uncommon. Other effects on mood, such as depression and anxiety, have been reported during post-marketing use, though their frequency is not known.

Q: What happens if Sarilen is taken past its expiration date?

A: Using any medication past its expiration date is generally not recommended by official guidance. The expiration date marks the period during which the drug is guaranteed to retain its full strength, quality, and purity when stored according to official requirements.

Q: Does Sarilen contain lactose or gluten?

A: Official documentation for the inactive ingredients (excipients) confirms that Losartan tablets contain lactose monohydrate. The official label does not list gluten as an ingredient.

How should Sarilen be stored and disposed of?

How to Store and Dispose of Sarilen

The storage and disposal of Sarilen (Losartan Potassium) must strictly follow the requirements defined in the official regulatory labeling to ensure product integrity and safety.


Storage Requirements

Sarilen must be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted temperature excursions. The tablets must be stored in the original, tightly closed container and must be protected from light and moisture. It is required to keep this medication out of the reach and sight of children and pets, and it must not be frozen.

Disposal Instructions

Unused or expired Sarilen should ideally be discarded through an official drug take-back program or mail-back envelope. If such a program is not available, the tablets can be mixed with an undesirable substance (like coffee grounds), placed in a sealed bag, and thrown into the household trash. The product should not be flushed down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sarilen found in:

A-Z Index: